10-Q/A: Dalrada Financial Corp Amends Q3 Report After Revenue Misstatement

Dalrada Financial Corporation has filed an amended 10-Q report to correct a misstatement in revenue and accounts receivable for the quarter ended March 31, 2024.

Summary

• Dalrada Financial Corporation filed an amendment to its quarterly report to correct revenue and accounts receivable figures for the period ending March 31, 2024.
• The company's total revenue for the quarter was $7,987,462, with $7,462,633 from third parties and $524,829 from related parties.
• The company reported a net loss of $5,225,936 for the quarter and $15,504,252 for the nine-month period.
• The company's cash and cash equivalents were $533,595 as of March 31, 2024.
• The company's total assets were $27,850,822 and total liabilities were $21,345,771 as of March 31, 2024.
• The company's accumulated deficit was $157,152,598 as of March 31, 2024.
• The company's operating expenses were $7,001,185 for the quarter and $19,271,273 for the nine-month period.
• The company's cost of revenues was $5,594,338 for the quarter and $13,717,562 for the nine-month period.

Sentiment

Score: 3

Explanation: The document reveals significant financial challenges, including substantial net losses, a large accumulated deficit, and concerns about the company's ability to continue as a going concern. While there are some positive aspects, such as revenue growth in the Genefic division, the overall sentiment is negative due to the company's financial instability and operational issues.

Positives

• Genefic division revenue increased by 31.8% for the three months ended March 31, 2024, compared to the same period in 2023.
• The company's working capital improved to $3,009,666 as of March 31, 2024, compared to a deficit of $202,420 as of June 30, 2023.

Negatives

• Dalrada Climate Technology revenue decreased by 59.7% for the three months ended March 31, 2024, compared to the same period in 2023.
• Dalrada Precision Manufacturing revenue decreased by 82.1% for the three months ended March 31, 2024, compared to the same period in 2023.
• Dalrada Technologies revenue decreased by 27.8% for the three months ended March 31, 2024, compared to the same period in 2023.
• The company reported a net loss of $5,225,936 for the quarter and $15,504,252 for the nine-month period.
• The company has a significant accumulated deficit of $157,152,598.
• The company's operating expenses were $7,001,185 for the quarter and $19,271,273 for the nine-month period.
• The company's cost of revenues was $5,594,338 for the quarter and $13,717,562 for the nine-month period.
• The company's cash and cash equivalents were $533,595 as of March 31, 2024.

Risks

• The company's net loss and limited working capital raise substantial doubt about its ability to continue as a going concern.
• The company will be required to raise substantial capital to fund its operations.
• The company is incurring increased costs as a result of being a publicly traded company.
• The company has material weaknesses in its internal control over financial reporting.
• The company is involved in ongoing legal proceedings.

Future Outlook

The company anticipates needing additional liquidity to fund operations and expansion, and plans to support operations by raising capital and accelerating sales and marketing efforts.

Management Comments

• Management is planning to support operations by raising capital, and by accelerating sales & marketing efforts of high-margin heating & cooling units, precision parts, Dalrada Energy Services, DepTecs deposition systems and COVID-19 testing.
• The continuation of the Company as a going concern is dependent upon the continued financial support from its management, its ability to obtain the necessary debt or equity financing and generate profitable operations from the Companys planned future operations.

Industry Context

The company operates in various sectors including healthcare, energy, manufacturing, and technology, and the results reflect the challenges and opportunities in these diverse markets.

Comparison to Industry Standards

• The company's performance is mixed across its different segments, with some showing growth while others are experiencing significant declines.
• The healthcare segment (Genefic) shows revenue growth, which is positive compared to industry trends in healthcare services.
• The energy segment (Dalrada Climate Technology) experienced a significant revenue decrease, which may be concerning compared to the growing demand for renewable energy solutions.
• The manufacturing segment (Dalrada Precision Manufacturing) also saw a substantial revenue decline, which is not in line with the general trend of increased manufacturing activity.
• The technology segment (Dalrada Technologies) experienced a revenue decrease, which is not in line with the general trend of increased technology spending.
• The company's overall net loss and negative cash flow from operations are concerning compared to industry benchmarks for profitability and financial stability.

Management Changes

Corporate Governance

Legal Proceedings

• Dalrada Health Products is involved in a lawsuit against Vivera Pharmaceuticals for misappropriation of funds.
• Kroger Specialty Pharmacy LLC filed lawsuits against Genefic Specialty Pharmacy and two of its employees for breach of non-compete agreements.
• Likido Ltd. was ordered to pay damages and legal costs in a dispute with MAPtech PACKAGING LIMITED.

Related Party Transactions

• The company received cash funding or expenses paid on behalf of the company from related parties totaling $1,059,600 and $4,993,838 for the three and nine months ended March 31, 2024, respectively.
• The company recorded revenues from related parties totaling $524,829 for the three months ended March 31, 2024, and $1,639,805 for the nine months ended March 31, 2024.
• Several notes payable are with related parties, bearing interest at 3% or 8% per annum.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and potential dilution from future equity sales.
• Employees may be affected by potential cost-cutting measures or restructuring due to the company's financial challenges.
• Customers may experience disruptions in service or product availability if the company's financial situation worsens.
• Suppliers and creditors face increased risk of non-payment due to the company's financial difficulties.

Next Steps

• The company plans to raise capital to fund operations and expansion.
• The company plans to accelerate sales and marketing efforts of high-margin products and services.
• The company will continue to rely on equity sales of its common shares to fund operations.

Key Dates

Keywords

financial results, revenue, net loss, accounts receivable, going concern, internal control, legal proceedings, stock compensation, operating expenses, cost of revenue